OncLive TV

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses whether biosimilars can replace biologics in oncology.

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses considerations for FDA-approved biosimilars.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses a personalized neoantigen-targeting vaccine for patients with glioblastoma.

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses the categorization of patients with triple-negative breast cancer.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the use of chemoimmunotherapy in patients with non–small cell lung cancer (NSCLC).

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses sequencing therapies in the treatment of patients with pancreatic cancer.

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.